Cargando…
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase (clinicaltrials.gov Identifier: 01649856) examined...
Autores principales: | Lugtenburg, Pieternella, Avivi, Irit, Berenschot, Henriette, Ilhan, Osman, Marolleau, Jean Pierre, Nagler, Arnon, Rueda, Antonio, Tani, Monica, Turgut, Mehmet, Osborne, Stuart, Smith, Rodney, Pfreundschuh, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664395/ https://www.ncbi.nlm.nih.gov/pubmed/28935843 http://dx.doi.org/10.3324/haematol.2017.173583 |
Ejemplares similares
-
Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021) -
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021) -
Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021) -
Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004) -
Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH
(etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)
chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)